Neurotrnasmission disorders
AssigneesIsis Innovation Limited, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
InventorsAngela Vincent, Werner Hoch
Life of this patent
Estimating the term…
Loading patent…
AssigneesIsis Innovation Limited, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
InventorsAngela Vincent, Werner Hoch
Estimating the term…
There is disclosed a method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK). One such method comprises a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders. Also disclosed are kits for use in the diagnosis of neurotransmission and subsequent developmental disorders.
A method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK).
An assay kit for diagnosing neurotransmission disorders in mammals comprising MuSK or an epitope thereof and means for contacting said MuSK with a bodily fluid from a mammal.
An isolated or purified antibody specific for an anti-MuSK autoantibody from a bodily fluid of a mammal.
A method for making a pharmaceutical formulation for the treatment of neurotransmission disorders, comprising the steps of generating and subsequently isolating an antibody specific for anti-MuSK autoantibody from a bodily fluid of a mammal, manufacturing bulk quantities of said antibody and formulating the antibody in a compound including a pharmaceutically acceptable carrier, diluent or excipient therefor.
A method of identifying compounds capable of alleviating or treating neurotransmission disorders, comprising the steps of contacting a candidate compound in the presence of MuSK or an epitope thereof and an antibody capable of binding MuSK, wherein a compound that prevents binding of said antibody to MuSK or an epitope thereof is a candidate for treating neurotransmission disorders.
Dependencies are inferred from the claim text.